Judy Wang

Before joining Morgan Lewis, Judy formerly worked for a leading US law firm on capital markets and mergers and acquisitions deals, where she represented various China-based companies in their US and Hong Kong listings, going private transactions, and post-initial public offering compliance matters.

Judy is admitted in New York in 2009, and also passed the Chinese bar examination in 2010.

Foreign Corrupt Practices Act (FCPA) Due Diligence

• Advised a leading pharmaceutical company in conducting FCPA due diligence review in connection with its $100 million equity investment in and exclusive license and collaboration agreement with a well-known public Chinese pharmaceutical company
• Represented a leading private equity investment firm, in conducting FCPA due diligence review in connection with its various equity investments in startups and medium-size companies that engage in IT, AI, retailing and education industries in China
• Advised a leading private equity investment firm, in conducting an FCPA due diligence review in connection with its global-wide acquisition of a medical product line of a Fortune 500 pharmaceuticals and healthcare company
• Advised a leading global solar energy company, in conducting an FCPA due diligence on a SOE investment target in China to identify areas of concern and recommend remediation measures and safeguards
• Advised a German-based Fortune 500 kidney dialysis company, in comprehensive FCPA and PRC anti-bribery law due diligence on its various acquisition targets in China, and on feasibility of restructuring of its sales and distribution model in China in compliance with FCPA and PRC anti-bribery laws
• Advised a leading petrochemical producer and manufacturer of woolen yarns, on its $225 million acquisition of China- and Hong Kong–based fiber manufacturers, including pre-acquisition FCPA due diligence on the potential targets
• Advised, in conducting FCPA due diligence on its proposed acquisition of a privately held Chinese construction company in China, including a comprehensive review of business model and marketing practices

Investigations and Reviews

• Advised a leading multinational pharmaceutical company in its internal investigation regarding its problematic engagement with the exclusive distributor for its major vaccine product
• Advised a leading multinational pharmaceutical company in its multiple internal investigations in Japan regarding Japan subsidiary’s speaking event practices and expenses
• Advised a leading multinational pharmaceutical company in conducting internal investigation related to whistleblower’s allegation against marketing leaders in China for sponsorship event issues
• Advised a US multinational software and engineering services company in conducting an internal investigation into a whistle-blower complaint about team members’ violation of non-compete obligations and other misconducts
• Represented a leading global manufacturer of optics and reprography products for a risk assessment under the PRC anti-corruption law on its proposed travel sponsorship program
• Advised a global medical device manufacturer in conducting an internal investigation related to a distributor’s complaint against its sales leaders and employees in China for channel stuffing issues
• Advised a global private education company in conducting an internal investigation into a whistle-blower complaint against the client’s joint venture in China (a well-known private university in which the Company owns a majority stake) about the possible false disclosures of the teaching data in the education quality evaluation hosted by China’s Ministry of Education
• Advised a leading global provider of vehicle rental and car sharing services in FCPA and PRC anti-bribery investigations involving self-reporting to US Department of Justice and US Securities and Exchange Commission
• Advised one of the world's largest for-profit higher education networks on internal investigations against local employees for alleged fraud, corruption and other misconduct; advised on restructuring of business practices and reviewing and improving FCPA compliance programs in China
• Advised a leading global solar power company, with internal investigation of its multiple China joint venture operations to measure compliance with FCPA and anti-bribery laws, including on-site interviews and gathering and review of company books and records
• Advised a global medical device company in developing a comprehensive anti-corruption and compliance program for Asia operations, helping to write and implement company compliance rules. Conduct FCPA and compliance reviews for daily operations and projects, including acquisitions, third party engagements, joint ventures, hosting events for government officials, sponsoring travel for government officials, and joint projects with public hospitals; conduct investigations into allegations of improper payments, thefts, and accounting practices.

Data Protection

• Advised Hewlett Packard Enterprise on China state secrecy law issues
• Advised Wolters Kluwer on its localization of subscription agreement and data privacy agreement.
• Advised various multinational companies on data collection, processing, transfer and marketing, promotion practices under the PRC data privacy regulations